|1.||Conley, Pamela B: 1 article (11/2003)|
|2.||Sinha, Uma: 1 article (11/2003)|
|3.||LaRocca, Thomas: 1 article (11/2003)|
|4.||Delaney, Suzanne M: 1 article (11/2003)|
|5.||Lin, Pei Hua: 1 article (11/2003)|
|6.||Phillips, David R: 1 article (11/2003)|
|7.||André, Patrick: 1 article (11/2003)|
|8.||Vincent, Diana: 1 article (11/2003)|
|9.||Scarborough, R M: 1 article (04/2000)|
|10.||Malinowski, J: 1 article (04/2000)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
04/21/2000 - "In the venous thrombosis model at the maximally effective dose, C921-78 had minimal extension of ex vivo clotting parameters, while enoxaparin and unfractionated heparin demonstrated a two to sevenfold increase in activated partial thromboplastin times, and PPACK had a threefold extension of thrombin clotting times. "
11/25/2003 - "Thrombin and TXA2 also synergized with P2Y12 in the absence of anticoagulation, because combined treatment of aspirin or C921-78 (a factor Xa inhibitor) with CT50547 or 2-MeSAMP (a P2Y12 antagonist) inhibited the thrombotic process, whereas all treatments failed to inhibit thrombosis when used individually. "
|3.||Thromboplastin (Tissue Factor)
|5.||Aspirin (Acetylsalicylic Acid)
|7.||phenylalanyl- prolyl- arginine- chloromethyl ketone (PPACK)